Abeona Therapeutics Inc.

Company Listings from SPi: Abeona Therapeutics Inc.

You are here: Home >> SPi Company Listings >> Abeona Therapeutics Inc.

 

Abeona Therapeutics Inc.

Website:
http://

Search for other references to "abeona" on SPi News

Latest Abeona Therapeutics Inc. News

Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs NEW YORK and CLEVELAND, June 26, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appoint...... 13:00 GMT Wednesday 26th June 2019

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U....... 13:29 GMT Tuesday 18th June 2019

Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Com...... 13:00 GMT Tuesday 21st May 2019

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB) NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Com...... 13:00 GMT Tuesday 14th May 2019

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019IND submitted for ABO-202 in CLN1 diseaseInvestor conference call on Tuesday, May 14 at 10:...... 21:15 GMT Friday 10th May 2019

Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-te...... 13:30 GMT Wednesday 8th May 2019

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences NEW YORK and CLEVELAND, May 07, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its particip...... 21:15 GMT Tuesday 7th May 2019

Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting NEW YORK and CLEVELAND, May 01, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that intravi...... 13:00 GMT Wednesday 1st May 2019

Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting NEW YORK and CLEVELAND, April 30, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today will report new prec...... 13:00 GMT Tuesday 30th April 2019

Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting NEW YORK and CLEVELAND, April 15, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new d...... 19:41 GMT Monday 15th April 2019

Buy Abeona Therapeutics Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us